DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in antiemetic therapies, personalized medicine, and digital health technologies.

Key companies developing therapies for Necrotizing Enterocolitis are - Abbott, Astellas Pharma Inc., Bayer HealthCare AG, Becton, Dickinson, and Company (BD), Bristol-Myers Squibb Company, Daiichi ...

As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that ...

DS-6000a: Daiichi Sankyo Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products ...

DelveInsight's CLK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development.

The progressive supranuclear palsy market is expected to witness steady growth due to increasing disease awareness, advancements in diagnosti ...

Tina Romero's 'Queens of the Dead' has been acquired by Independent Film Company & Shudder for release in North American theaters this fall.